Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

ClinicalTrials.gov ID: NCT00117884

Public ClinicalTrials.gov record NCT00117884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.

Study identification

NCT ID: NCT00117884
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Takeda; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Papillomavirus Infections

Interventions

851B Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 40 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2006 (Type not available)
Primary completion: Jun 2008 (Actual)
Completion: Jun 2008 (Actual)
Last update posted: Aug 19, 2016

2006 – 2008

United States locations

U.S. sites: 22
U.S. states: 14
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Colton	California	92324	—
Not listed	San Diego	California	92108	—
Not listed	Colorado Springs	Colorado	80910	—
Not listed	Boynton Beach	Florida	33461	—
Not listed	Tampa	Florida	33607	—
Not listed	Augusta	Georgia	30912	—
Not listed	Savannah	Georgia	31405	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Detroit	Michigan	48201	—
Not listed	Moorestown	New Jersey	08057	—
Not listed	New York	New York	10032	—
Not listed	Charlotte	North Carolina	28203	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Arlington	Texas	76012	—
Not listed	Austin	Texas	78705	—
Not listed	Houston	Texas	77004	—
Not listed	Renton	Washington	98055	—
Not listed	Seattle	Washington	98105	—
Not listed	Spokane	Washington	99207	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00117884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 19, 2016 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00117884 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →